CiVi Biopharma is a clinical-stage research and development biotechnology company. It focuses on creating therapies for cardiovascular, metabolic, and related diseases. CiVi Biopharma's pipeline includes CiVi007, a molecule developed for the treatment of hypercholesterolemia and the prevention of cardiovascular disease. In addition, it has other clinical-stage development program activities aimed at treating severe liver diseases.